switched from compounded to brand and the titration reset itself
switched from compounded to brand and the titration reset itself. I have gone back and forth on this for months.
Concentration on the compounded vial was different from what I had been using and I nearly did the arithmetic on autopilot.
Nothing in this thread is medical advice, and the choice between arrangements is one for you and a prescriber who knows your history.
Asked which facility and got a name straight away. Looked it up, found the registration, felt considerably better about the whole thing.
I will update this if the picture changes rather than quietly leaving it up.
best — the order this archive was captured in
A beyond-use date derived from published stability data means something different from one assigned by default rule. Asking which is a fair question and the answer is usually available.
Salt form matters for mass: a preparation specified as one salt and dosed as the free base gives you a different amount of peptide for the same number on the label.
Is the compound still on the shortage list where you are?
a 503B has to register and report, so there is a paper trail to ask for
Agreed on potency testing of the finished preparation. That is a different question from the purity of the starting material.
Kept the label from every vial. When the shortage status changed, having the paper trail made the conversation much shorter.
This. Compounded preparations carry no equivalence claim, and treating them as generics is a category error people make constantly.
Why "compounded" is not "generic", written out because the confusion is constant.
A generic is an approved product demonstrated to be bioequivalent to a reference. A compounded preparation is made for a patient or, in the case of an outsourcing facility, under a different regulatory route entirely. It carries no equivalence claim and it is not required to demonstrate one.
That is not a quality judgement. Plenty of compounded preparations are made carefully in facilities with real testing programmes. It is a statement about what has and has not been established, and the difference matters when people assume the two are interchangeable.
shortage status changes and the whole arrangement changes with it
That is not what patient-specific means. It refers to the prescription, not to a customisation of the formula.
Compounded preparations are not approved products and carry no bioequivalence claim. That is a statement about regulatory category, not about quality.
What is the beyond-use date and what is it based on?
- 1A beyond-use date derived from published stability data means something…6 comments in this branch · started by u/marit_laurent
- 2This. Compounded preparations carry no equivalence claim, and treating them…6 comments in this branch · started by u/naomi_erdogan